Insulin-like growth factor- I (IGF-I) is a ubiquitously expressed 7.5 kDa polypedtide that circulate in relatively high concentrations. In bone, IGF-I is secreted by osteoblasts, and is stored in the matrix bound to IGF binding proteins (IGFBPs). Skeletal IGF-I promotes osteoblast differentiation, increasing collagen biosynthesis and mildly enhancing bone cell mitogenesis. Reduced serum IGF-I concentrations have been linked to lower skeletal levels of this peptide, future risk of hip fracture, histomorphometric indices of bone formation, bone mineral density, and a poly-morphism in the IGF-I gene. Hence serum IGF-I has been considered an intermediate skeletal phenotype. In the first three years of our proposal, using inbred strains of mice have established: 1) serum IGF-I is a heritable polygenic train; 2) three major non-growth hormone dependent quantitative trait loci (QTLs) and one interactive QTL influence the serum IGF-I phenotype; 3) two IGF-I QTLs associate with major skeletal phenotypes (BMD and femoral length); 4) one QTL contains the IGF-I gene and the interactive QTL maps in close proximity to the IGFBP-3 gene; 5) congenic mice carrying one of these major QTLs exhibit reduced serum IGF-I and a major skeletal phenotype; and 6) osteoblasts from high serum IGF-I mice (C3H/HeJ) show a sixfold up-regulation in IGF-I exon 1 promoter mRNA compared to the low serum IGF-I mice (C57BL/6). These data suggest that IGF-I is important for the acquisition of BMD and optimal strength. In this proposal we hypothesize that serum IGF-I genes are also major determinants of skeletal IGF-I expression. Our goals are to fine map these IGF-I regulatory genes and to understand how these genes affect osteoblast function and bone morphology. We propose three specific aims: 1) to delineate the genes for serum IGF-I by fine mapping and assessing nested congenics for changes in BMD and strength; 2) to determine the role of IGFBPs in modulating skeletal IGF-I by studying osteoblast expression and secretion of IGFBPs and by phenotype 'rescue' of newly developed congenics through targeted over expression of skeletal IGF-I; and 3) to determine the molecular mechanisms responsible for interstrain differences in skeletal IGF-I expression. These experiments will provide tremendous insight into the cellular regulation of the IGFs and IGFBPs, an important first stem towards understanding the role of IGF-I in osteoporosis and other chronic disease wherein tissue specific IGF-I activity may have a major pathophysiologic component.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR045433-05
Application #
6511929
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Program Officer
Sharrock, William J
Project Start
1998-07-22
Project End
2005-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
5
Fiscal Year
2002
Total Cost
$775,673
Indirect Cost
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Guntur, Anyonya R; Le, Phuong T; Farber, Charles R et al. (2014) Bioenergetics during calvarial osteoblast differentiation reflect strain differences in bone mass. Endocrinology 155:1589-95
Motyl, Katherine J; Bishop, Kathleen A; DeMambro, Victoria E et al. (2013) Altered thermogenesis and impaired bone remodeling in Misty mice. J Bone Miner Res 28:1885-97
Smith, Spenser S; Kessler, Catherine B; Shenoy, Vikram et al. (2013) IGF-I 3' untranslated region: strain-specific polymorphisms and motifs regulating IGF-I in osteoblasts. Endocrinology 154:253-62
Rahman, Sima; Lu, Yalin; Czernik, Piotr J et al. (2013) Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. Endocrinology 154:2687-701
Wu, Yingjie; Sun, Hui; Basta-Pljakic, Jelena et al. (2013) Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor. J Bone Miner Res 28:1575-86
Kawai, Masanobu; Rosen, Clifford J (2012) The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am 41:323-33, vi
Guntur, Anyonya R; Rosen, Clifford J (2012) Bone as an endocrine organ. Endocr Pract 18:758-62
Xian, Lingling; Wu, Xiangwei; Pang, Lijuan et al. (2012) Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 18:1095-101
Motyl, Katherine J; Rosen, Clifford J (2012) The skeleton and the sympathetic nervous system: it's about time! J Clin Endocrinol Metab 97:3908-11
Guntur, Anyonya R; Rosen, Clifford J; Naski, Michael C (2012) N-cadherin adherens junctions mediate osteogenesis through PI3K signaling. Bone 50:54-62

Showing the most recent 10 out of 61 publications